HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

<h4>Objective</h4>To compare changes over 48 weeks in body fat, lipids, Metabolic Syndrome and cardiovascular disease risk between patients randomised 1:1 to lopinavir/ritonavir (r/LPV) plus raltegravir (RAL) compared to r/LPV plus 2-3 nucleoside/nucleotide reverse transcriptase inhibito...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Allison Martin, Cecilia L Moore, Patrick W G Mallon, Jennifer F Hoy, Sean Emery, Waldo H Belloso, Praphan Phanuphak, Samuel Ferret, David A Cooper, Mark A Boyd, Second-Line Study Team
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6772b8ad696a47bba3dd3cf42eb38743
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6772b8ad696a47bba3dd3cf42eb38743
record_format	dspace
spelling	oai:doaj.org-article:6772b8ad696a47bba3dd3cf42eb387432021-11-18T08:49:02ZHIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.1932-620310.1371/journal.pone.0077138https://doaj.org/article/6772b8ad696a47bba3dd3cf42eb387432013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24204757/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>To compare changes over 48 weeks in body fat, lipids, Metabolic Syndrome and cardiovascular disease risk between patients randomised 1:1 to lopinavir/ritonavir (r/LPV) plus raltegravir (RAL) compared to r/LPV plus 2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) as second-line therapy.<h4>Methods</h4>Participants were HIV-1 positive (>16 years) failing first-line treatment (2 consecutive HIV RNA >500 copies/mL) of NNRTI +2N(t)RTI. Whole body dual energy x-ray absorptiometry was performed at baseline and week 48. Data were obtained to calculate the Metabolic Syndrome and Framingham cardiovascular disease (CVD) risk score. Linear regression was used to compare mean differences between arms. Logistic regression compared incidence of metabolic syndrome. Associations between percent limb fat changes at 48 weeks with baseline variables were assessed by backward stepwise multivariate linear regression. Analyses were adjusted for gender, body mass index and smoking status.<h4>Results</h4>210 participants were randomised. The mean (95% CI) increase in limb fat over 48 weeks was 15.7% (5.3, 25.9) or 0.9 kg (0.2, 1.5) in the r/LPV+N(t)RTI arm and 21.1% (11.1, 31,1) or 1.3 kg (0.7, 1.9) in the r/LPV+RAL arm, with no significant difference between treatment arms (-5.4% [-0.4 kg], p>0.1). Increases in total body fat mass (kg) and trunk fat mass (kg) were also similar between groups. Total:HDL cholesterol ratio was significantly higher in the RAL arm (mean difference -0.4 (1.4); p = 0.03), there were no other differences in lipid parameters between treatment arms. There were no statistically significant differences in CVD risk or incidence of Metabolic Syndrome between the two treatment arms. The baseline predictors of increased limb fat were high viral load, high insulin and participant's not taking lipid lowering treatment.<h4>Conclusion</h4>In patients switching to second line therapy, r/LPV combined with RAL demonstrated similar improvements in limb fat as an N(t)RTI + r/LPV regimen, but a worse total:HDL cholesterol ratio over 48 weeks.<h4>Trial registration</h4>This clinical trial is registered on Clinicaltrials.gov, registry number NCT00931463 http://clinicaltrials.gov/ ct2/show/NCT00931463?term = NCT00931463&rank = 1.Allison MartinCecilia L MoorePatrick W G MallonJennifer F HoySean EmeryWaldo H BellosoPraphan PhanuphakSamuel FerretDavid A CooperMark A BoydSecond-Line Study TeamPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 10, p e77138 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Allison Martin Cecilia L Moore Patrick W G Mallon Jennifer F Hoy Sean Emery Waldo H Belloso Praphan Phanuphak Samuel Ferret David A Cooper Mark A Boyd Second-Line Study Team HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
description	<h4>Objective</h4>To compare changes over 48 weeks in body fat, lipids, Metabolic Syndrome and cardiovascular disease risk between patients randomised 1:1 to lopinavir/ritonavir (r/LPV) plus raltegravir (RAL) compared to r/LPV plus 2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) as second-line therapy.<h4>Methods</h4>Participants were HIV-1 positive (>16 years) failing first-line treatment (2 consecutive HIV RNA >500 copies/mL) of NNRTI +2N(t)RTI. Whole body dual energy x-ray absorptiometry was performed at baseline and week 48. Data were obtained to calculate the Metabolic Syndrome and Framingham cardiovascular disease (CVD) risk score. Linear regression was used to compare mean differences between arms. Logistic regression compared incidence of metabolic syndrome. Associations between percent limb fat changes at 48 weeks with baseline variables were assessed by backward stepwise multivariate linear regression. Analyses were adjusted for gender, body mass index and smoking status.<h4>Results</h4>210 participants were randomised. The mean (95% CI) increase in limb fat over 48 weeks was 15.7% (5.3, 25.9) or 0.9 kg (0.2, 1.5) in the r/LPV+N(t)RTI arm and 21.1% (11.1, 31,1) or 1.3 kg (0.7, 1.9) in the r/LPV+RAL arm, with no significant difference between treatment arms (-5.4% [-0.4 kg], p>0.1). Increases in total body fat mass (kg) and trunk fat mass (kg) were also similar between groups. Total:HDL cholesterol ratio was significantly higher in the RAL arm (mean difference -0.4 (1.4); p = 0.03), there were no other differences in lipid parameters between treatment arms. There were no statistically significant differences in CVD risk or incidence of Metabolic Syndrome between the two treatment arms. The baseline predictors of increased limb fat were high viral load, high insulin and participant's not taking lipid lowering treatment.<h4>Conclusion</h4>In patients switching to second line therapy, r/LPV combined with RAL demonstrated similar improvements in limb fat as an N(t)RTI + r/LPV regimen, but a worse total:HDL cholesterol ratio over 48 weeks.<h4>Trial registration</h4>This clinical trial is registered on Clinicaltrials.gov, registry number NCT00931463 http://clinicaltrials.gov/ ct2/show/NCT00931463?term = NCT00931463&rank = 1.
format	article
author	Allison Martin Cecilia L Moore Patrick W G Mallon Jennifer F Hoy Sean Emery Waldo H Belloso Praphan Phanuphak Samuel Ferret David A Cooper Mark A Boyd Second-Line Study Team
author_facet	Allison Martin Cecilia L Moore Patrick W G Mallon Jennifer F Hoy Sean Emery Waldo H Belloso Praphan Phanuphak Samuel Ferret David A Cooper Mark A Boyd Second-Line Study Team
author_sort	Allison Martin
title	HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
title_short	HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
title_full	HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
title_fullStr	HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
title_full_unstemmed	HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
title_sort	hiv lipodystrophy in participants randomised to lopinavir/ritonavir (lpv/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (n(t)rti) or lpv/r + raltegravir as second-line antiretroviral therapy.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/6772b8ad696a47bba3dd3cf42eb38743
work_keys_str_mv	AT allisonmartin hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy AT cecilialmoore hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy AT patrickwgmallon hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy AT jenniferfhoy hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy AT seanemery hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy AT waldohbelloso hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy AT praphanphanuphak hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy AT samuelferret hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy AT davidacooper hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy AT markaboyd hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy AT secondlinestudyteam hivlipodystrophyinparticipantsrandomisedtolopinavirritonavirlpvr23nucleosidenucleotidereversetranscriptaseinhibitorsntrtiorlpvrraltegravirassecondlineantiretroviraltherapy
_version_	1718421266392678400

HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

Ejemplares similares